Stereotaxis began as a research project--developing a magnetic surgical guidance system--that serendipitously became a company without much regard for commercial prospects. The original design was ahead of the technology curve, but innovations in magnetic and imaging systems fortuitously enabled Stereotaxis to turn this concept into a product. The company's system, however, was and still remains far ahead of the necessary adjunctive drugs and devices necessary to become a viable therapeutic tool in neurology, the area Stereotaxis first sought to pursue. Looking for applications in other specialties for what it believes is a platform technology, Stereotaxis shifted its focus to cardiology. The company launched a system that has been well-received in the small but growing area of electrophysiology. Most recently, Stereotaxis has begun to focus on what could be its most significant opportunity: interventional cardiology. Here, too, the company appears to be the beneficiary of good timing: in the era of drug-eluting stents, interventionalists are likely to treat more difficult patients, the cases that could benefit most from Stereotaxis' advanced guidance system. The company's system, however, was and still remains far ahead of the adjunctive drugs and devices necessary to become a viable therapeutic tool in neurology, the area Stereotaxis first sought to pursue.
By Stephen Levin
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.
Crystal Qin has led LaNova Medicines’ swift rise in the biotech world through strategic partnerships and innovative R&D, highlighted by a record deal with big pharma.
In Vivo Rising Leader Amir Hefni, CEO of Resolution Therapeutics, discusses the company's advancements in macrophage cell therapies for inflammatory and fibrotic diseases, and his transition from big pharma to biotech leadership.
The sixth annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
